Over several months in 2017, a top Purdue Pharma executive and the head of the Addiction Policy Forum, a controversial patient advocacy group, discussed the possibility of working together to combat opioid addiction, according to emails reviewed by STAT.
One potential project concerned providing educational resources to people struggling with addiction issues, which the Addiction Policy Forum sought to launch. This occurred around the same time that the pharmaceutical industry trade group, PhRMA, was looking to its members — which included Purdue — to contribute to a multi-year, multi-million-dollar grant soon to be awarded to the advocacy group, the emails noted.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
